L
Lumos Diagnostics (ASX:LDX) specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.
Investor insights
Funding rounds participated in
$18M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Funding rounds raised
Total raised
$18M
from investors over 1 rounds
L
Lumos Diagnostics raised $18M on November 6, 2020